{"id":12536,"date":"2023-11-17T09:42:19","date_gmt":"2023-11-17T08:42:19","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?p=12536"},"modified":"2026-02-27T11:26:07","modified_gmt":"2026-02-27T10:26:07","slug":"sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/","title":{"rendered":"\u00abSustainable Development Goals\u00bb: Bayer d\u00e9veloppe avec l\u2019Institut Swiss TPH un traitement contre les maladies parasitaires chez l\u2019Homme"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/interpharma.ch\/wp-content\/uploads\/2023\/11\/doctor_examining_african_girl-2-1024x683.jpeg\" alt=\"\" class=\"wp-image-22970\"\/><\/figure>\n\n\n\n<p class=\"is-style-paragraph-lead-text\">Les infections transmises par des vers parasites pr\u00e9sents dans le sol affectent les groupes de population les plus pauvres et les plus d\u00e9favoris\u00e9s. Dans le monde, plus de 1,5\u00a0milliard de personnes sont infect\u00e9es par au moins une de ces esp\u00e8ces de vers parasites. <\/p>\n\n\n\n<p>Bayer et l\u2019Institut tropical et de sant\u00e9 publique suisse (Swiss TPH) collaborent dans le cadre du d\u00e9veloppement clinique d\u2019un principe actif pour traiter les personnes infect\u00e9es par les helminthes, transmis par le sol. Cette collaboration s\u2019appuie sur les r\u00e9sultats positifs d\u2019une \u00e9tude de phase&nbsp;II men\u00e9e par Swiss TPH et ses partenaires en Tanzanie. Publi\u00e9e le 18&nbsp;mai&nbsp;2023 dans le New England Journal of Medicine, elle d\u00e9montre la bonne efficacit\u00e9 d\u2019un principe actif administr\u00e9 aux patients atteints d\u2019infections \u00e0 Trichuris trichiura ainsi qu\u2019\u00e0 Ancylostoma duodenale et Necator americanus.<\/p>\n\n\n\n<p>\u00ab&nbsp;Bayer s\u2019engage dans la lutte contre les maladies tropicales n\u00e9glig\u00e9es&nbsp;\u00bb, affirme Christian Rommel, responsable de la recherche et du d\u00e9veloppement et membre de la direction de Bayer Pharmaceuticals. \u00ab&nbsp;Le d\u00e9veloppement du principe actif avec l\u2019\u00e9quipe de Swiss TPH illustre la mani\u00e8re dont nous rassemblons nos forces pour mettre au point de nouvelles m\u00e9thodes de traitements destin\u00e9s aux patientes et patients infect\u00e9s par les helminthes.&nbsp;\u00bb<\/p>\n\n\n\n<p>Le principe actif est un anthelminthique, efficace contre plusieurs maladies parasitaires, mais pas encore autoris\u00e9 pour une utilisation chez l\u2019Homme. Dans le cadre d\u2019\u00e9tudes de phase&nbsp;II, les chercheurs du Swiss TPH et de ses partenaires en Tanzanie ont d\u00e9montr\u00e9 son efficacit\u00e9 sur des personnes atteintes d\u2019infections \u00e0 Trichuris trichiura ainsi qu\u2019\u00e0 Ancylostoma duodenale et Necator americanus sur l\u2019\u00eele de Pemba.<\/p>\n\n\n\n<p>Le principe actif a affich\u00e9 un succ\u00e8s th\u00e9rapeutique \u00e9lev\u00e9 pour tous les helminthes transmis par le sol examin\u00e9s. La plus faible dose test\u00e9e \u00e9tait efficace chez 83&nbsp;% des personnes atteintes d\u2019infections \u00e0 Trichuris trichiuria. L\u2019augmentation de la dose a fait grimper le taux de gu\u00e9rison \u00e0 92&nbsp;%. \u00ab&nbsp;Un taux si \u00e9lev\u00e9 n\u2019avait encore jamais \u00e9t\u00e9 observ\u00e9 dans le traitement des personnes atteintes d\u2019infections \u00e0 Trichuris trichiuria avec les anthelminthiques actuellement disponibles&nbsp;\u00bb, souligne la Professeure Jennifer Keiser, responsable de l\u2019\u00e9tude.<\/p>\n\n\n\n<p>\u00ab&nbsp;Notre partenariat avec Bayer a pour objectif le d\u00e9veloppement commun d\u2019un traitement efficace pour les personnes infect\u00e9es par des helminthes transmis par le sol&nbsp;\u00bb, explique J\u00fcrg Utzinger, directeur de Swiss TPH. \u00ab&nbsp;M\u00eame s\u2019il existe des m\u00e9dicaments pour traiter cette infection, d\u2019autres th\u00e9rapies efficaces sont indispensables, en particulier compte tenu du risque d\u2019apparition de r\u00e9sistances aux traitements actuels.&nbsp;\u00bb<\/p>\n\n\n\n<p>Les infections parasitaires affectent les personnes des r\u00e9gions les plus pauvres et les plus d\u00e9favoris\u00e9es ayant un acc\u00e8s limit\u00e9 \u00e0 l\u2019eau potable, aux installations sanitaires et \u00e0 l\u2019hygi\u00e8ne, dans les zones tropicales et subtropicales. La pr\u00e9valence la plus \u00e9lev\u00e9e concerne l\u2019Afrique subsaharienne, l\u2019Asie et l\u2019Am\u00e9rique du Sud.<\/p>\n\n\n\n<p>Les infections \u00e0 helminthes transmis par le sol sont provoqu\u00e9es par diff\u00e9rentes esp\u00e8ces de vers parasites, dont Trichuris trichiura, Ancylostoma duodenale et Necator americanus. Les personnes infect\u00e9es peuvent d\u00e9velopper des sympt\u00f4mes tels que des douleurs abdominales, des diarrh\u00e9es et une an\u00e9mie, et les infections graves peuvent entra\u00eener une sous-alimentation, des troubles de croissance et un retard de d\u00e9veloppement physique. Dans les cas s\u00e9v\u00e8res, une occlusion intestinale n\u00e9cessitant une chirurgie peut \u00e9galement survenir. Dans le monde, plus de 1,5&nbsp;milliard de personnes sont infect\u00e9es par au moins une esp\u00e8ce de ces helminthes transmis par le sol.<\/p>\n\n\n\n<p>La collaboration avec Swiss TPH vient compl\u00e9ter le partenariat de d\u00e9veloppement de produits existant entre Bayer et la Drugs for Neglected Diseases Initiative (DNDi) pour mettre au point une option de traitement contre l\u2019onchocercose (dite \u00ab&nbsp;c\u00e9cit\u00e9 des rivi\u00e8res&nbsp;\u00bb), qui permettrait de r\u00e9duire consid\u00e9rablement la dur\u00e9e du traitement et de contr\u00f4ler la maladie \u00e0 terme.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Les infections transmises par des vers parasites pr\u00e9sents dans le sol affectent les groupes de population les plus pauvres et les plus d\u00e9favoris\u00e9s. Dans le monde, plus de 1,5\u00a0milliard de personnes sont infect\u00e9es par au moins une de ces esp\u00e8ces de vers parasites. Bayer et l\u2019Institut tropical et de sant\u00e9 publique suisse (Swiss TPH) collaborent [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3052,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[],"class_list":["post-12536","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>\u00abSustainable Development Goals\u00bb: Bayer d\u00e9veloppe avec l\u2019Institut Swiss TPH un traitement contre les maladies parasitaires chez l\u2019Homme - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00abSustainable Development Goals\u00bb: Bayer d\u00e9veloppe avec l\u2019Institut Swiss TPH un traitement contre les maladies parasitaires chez l\u2019Homme\" \/>\n<meta property=\"og:description\" content=\"Les infections transmises par des vers parasites pr\u00e9sents dans le sol affectent les groupes de population les plus pauvres et les plus d\u00e9favoris\u00e9s. Dans le monde, plus de 1,5\u00a0milliard de personnes sont infect\u00e9es par au moins une de ces esp\u00e8ces de vers parasites. Bayer et l\u2019Institut tropical et de sant\u00e9 publique suisse (Swiss TPH) collaborent [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-17T08:42:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-27T10:26:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/11\/female_doctor_examining_african_child-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1709\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"berta_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"berta_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/\"},\"author\":{\"name\":\"berta_admin\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\"},\"headline\":\"\u00abSustainable Development Goals\u00bb: Bayer d\u00e9veloppe avec l\u2019Institut Swiss TPH un traitement contre les maladies parasitaires chez l\u2019Homme\",\"datePublished\":\"2023-11-17T08:42:19+00:00\",\"dateModified\":\"2026-02-27T10:26:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/\"},\"wordCount\":704,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/11\/female_doctor_examining_african_child-scaled.jpeg\",\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/\",\"name\":\"\u00abSustainable Development Goals\u00bb: Bayer d\u00e9veloppe avec l\u2019Institut Swiss TPH un traitement contre les maladies parasitaires chez l\u2019Homme - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/11\/female_doctor_examining_african_child-scaled.jpeg\",\"datePublished\":\"2023-11-17T08:42:19+00:00\",\"dateModified\":\"2026-02-27T10:26:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/11\/female_doctor_examining_african_child-scaled.jpeg\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/11\/female_doctor_examining_african_child-scaled.jpeg\",\"width\":2560,\"height\":1709},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00abSustainable Development Goals\u00bb: Bayer d\u00e9veloppe avec l\u2019Institut Swiss TPH un traitement contre les maladies parasitaires chez l\u2019Homme\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\",\"name\":\"berta_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"caption\":\"berta_admin\"},\"sameAs\":[\"https:\/\/interpharma.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u00abSustainable Development Goals\u00bb: Bayer d\u00e9veloppe avec l\u2019Institut Swiss TPH un traitement contre les maladies parasitaires chez l\u2019Homme - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/","og_locale":"fr_FR","og_type":"article","og_title":"\u00abSustainable Development Goals\u00bb: Bayer d\u00e9veloppe avec l\u2019Institut Swiss TPH un traitement contre les maladies parasitaires chez l\u2019Homme","og_description":"Les infections transmises par des vers parasites pr\u00e9sents dans le sol affectent les groupes de population les plus pauvres et les plus d\u00e9favoris\u00e9s. Dans le monde, plus de 1,5\u00a0milliard de personnes sont infect\u00e9es par au moins une de ces esp\u00e8ces de vers parasites. Bayer et l\u2019Institut tropical et de sant\u00e9 publique suisse (Swiss TPH) collaborent [&hellip;]","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/","og_site_name":"Interpharma","article_published_time":"2023-11-17T08:42:19+00:00","article_modified_time":"2026-02-27T10:26:07+00:00","og_image":[{"width":2560,"height":1709,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/11\/female_doctor_examining_african_child-scaled.jpeg","type":"image\/jpeg"}],"author":"berta_admin","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"berta_admin","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/"},"author":{"name":"berta_admin","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818"},"headline":"\u00abSustainable Development Goals\u00bb: Bayer d\u00e9veloppe avec l\u2019Institut Swiss TPH un traitement contre les maladies parasitaires chez l\u2019Homme","datePublished":"2023-11-17T08:42:19+00:00","dateModified":"2026-02-27T10:26:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/"},"wordCount":704,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/11\/female_doctor_examining_african_child-scaled.jpeg","inLanguage":"fr-FR","copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/","name":"\u00abSustainable Development Goals\u00bb: Bayer d\u00e9veloppe avec l\u2019Institut Swiss TPH un traitement contre les maladies parasitaires chez l\u2019Homme - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/11\/female_doctor_examining_african_child-scaled.jpeg","datePublished":"2023-11-17T08:42:19+00:00","dateModified":"2026-02-27T10:26:07+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/11\/female_doctor_examining_african_child-scaled.jpeg","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/11\/female_doctor_examining_african_child-scaled.jpeg","width":2560,"height":1709},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/sustainable-development-goals-bayer-entwickelt-gemeinsam-mit-schweizer-institut-tph-behandlung-gegen-wurmerkrankungen-im-menschen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"\u00abSustainable Development Goals\u00bb: Bayer d\u00e9veloppe avec l\u2019Institut Swiss TPH un traitement contre les maladies parasitaires chez l\u2019Homme"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818","name":"berta_admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","caption":"berta_admin"},"sameAs":["https:\/\/interpharma.ch"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=12536"}],"version-history":[{"count":2,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12536\/revisions"}],"predecessor-version":[{"id":14449,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12536\/revisions\/14449"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/3052"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=12536"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=12536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}